Abstract
Current techniques for imaging prostate cancer (CT, MRI, and PET agents 18F-fluorodeoxyglucose, 11C-choline, 11C-acetate, and 18F-fluciclovine) are limited in sensitivity and specificity. PSMA PET agent 68Ga-PSMA-11 has recently been approved by the FDA. We comment on the performance of novel PSMA agent 18F-DCFPyL-PET/CT.
See related article by Morris et al., p. 3674
©2021 American Association for Cancer Research.
2021
American Association for Cancer Research.
You do not currently have access to this content.